Anders E Lilja

age ~52

from Bronx, NY

Get Report

Connected to:

Anders Lilja Phones & Addresses

Bronx, NY
22 Clarendon Ave, Somerville, MA 02144 • 6177645425
22 Clarendon Ave #2, Somerville, MA 02144 • 6177645425
282 Witherspoon St, Princeton, NJ 08542
1002 Deer Creek Dr, Plainsboro, NJ 08536
4613 Calvert Rd, College Park, MD 20740 • 3018643985
Cambridge, MA

Work

Company:

Novartis vaccines and diagnostics
Mar 2013
Address:

Cambridge, MA
Position:

Research investigator i

Education

Degree:

Ph.D.
School / High School:

University of Maryland College Park
1997 to 2002
Specialities:

Biochemistry

Skills

Vaccines • Virology • DNA • Agarose Gel Electrophoresis • Bacterial Transformation • Subcloning • Site-directed Mutagenesis • Primer Design • DNA extraction • RNA isolation • Northern Blotting • Transfection • Vector NTI • recombinant DNA technology • Viruses • Molecular Biology • Biotechnology • Tissue Culture • Gene Expression • cDNA • Electroporation • Gel Extraction • Nanodrop • Restriction Mapping • Miniprep • Vector Cloning

Languages

English • Swedish • German

Industries

Biotechnology

Resumes

Director, Virology & Molecular Biology At Batavia Bioservices

view source

Position:

Director, Virology & Molecular Biology at Batavia Bioservices

Location:

Greater Boston Area

Industry:

Biotechnology

Work:

Novartis Vaccines and Diagnostics - Cambridge, MA since Mar 2013
Research Investigator I
Novartis Vaccines and Diagnostics since Sep 2010
Associate Project Leader
Novartis Vaccines and Diagnostics - Cambridge, MA Sep 2011 - Feb 2013
Investigator II
Novartis Vaccines and Diagnostics - Cambridge, MA Mar 2009 - Sep 2011
Investigator I
Princeton University - Princeton, NJ Sep 2002 - Jan 2009
Postdoc

Education:

University of Maryland College Park 1997 - 2002
Ph.D., Biochemistry Chalmers University of Technology 1992 - 1996
M.Sc., Chemical Engineering

Skills:

Vaccines
Virology
DNA
Agarose Gel Electrophoresis
Bacterial Transformation
Subcloning
Site-directed Mutagenesis
Primer Design
DNA extraction
RNA isolation
Northern Blotting
Transfection
Vector NTI
recombinant DNA technology
Viruses
Molecular Biology
Biotechnology
Tissue Culture
Gene Expression
cDNA
Electroporation
Gel Extraction
Nanodrop
Restriction Mapping
Miniprep
Vector Cloning

Languages:

English
Swedish
German

Us Patents

Antigen Delivery Platforms
view source
US Patent:

20140030292, Jan 30, 2014
Filed:

Oct 11, 2011
Appl. No.:

13/878835
Inventors:

Michael Franti - Redding CT, US
Anders Lilja - Somerville MA, US
Rebecca Loomis - Philadelphia PA, US
Peter Mason - Somerville MA, US
Assignee:

Novartis AG - Basel
International Classification:

C07K 14/005
C12N 15/86
US Classification:

4242291, 536 2372, 435 704, 435375, 536 231, 4353201
Abstract:

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

Antigen Delivery Platforms
view source
US Patent:

20220213149, Jul 7, 2022
Filed:

Mar 16, 2022
Appl. No.:

17/696143
Inventors:

- Rixensart, BE
Anders LILJA - Somerville MA, US
Rebecca LOOMIS - Philadelphia PA, US
Peter W. MASON - Somerville MA, US
Assignee:

GLAXOSMITHKLINE BIOLOGICALS SA - Rixensart
International Classification:

C07K 14/005
C12N 15/86
A61K 39/12
Abstract:

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

Antigen Delivery Platforms
view source
US Patent:

20190144507, May 16, 2019
Filed:

Aug 28, 2018
Appl. No.:

16/114621
Inventors:

- Rixensart, BE
Anders Lilja - Somerville MA, US
Rebecca Loomis - Philadelphia, PA
Peter Mason - Somerville MA, US
Assignee:

GLAXOSMITHKLINE BIOLOGICALS, SA - Rixensart
International Classification:

C07K 14/005
C12N 15/86
A61K 39/12
Abstract:

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.